Structure Therapeutics Inc (GPCR)
41.75
+0.22
(+0.53%)
USD |
NASDAQ |
Sep 27, 16:00
41.65
-0.10
(-0.24%)
After-Hours: 20:00
Structure Therapeutics Cash from Investing (Quarterly): -204.52M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -204.52M |
| March 31, 2024 | 1.418M |
| December 31, 2023 | -180.74M |
| September 30, 2023 | 30.13M |
| June 30, 2023 | -68.71M |
| Date | Value |
|---|---|
| March 31, 2023 | -49.02M |
| December 31, 2022 | 10.34M |
| September 30, 2022 | -16.66M |
| June 30, 2022 | -16.07M |
| March 31, 2022 | -39.72M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-204.52M
Minimum
Jun 2024
30.13M
Maximum
Sep 2023
-53.35M
Average
-28.19M
Median
Cash from Investing (Quarterly) Benchmarks
| Viking Therapeutics Inc | -126.06M |
| Eli Lilly and Co | -2.199B |
| Novo Nordisk AS | -2.998B |
| Amgen Inc | -217.00M |
| Pfizer Inc | 4.60B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -26.39M |
| Cash from Financing (Quarterly) | 514.70M |
| Free Cash Flow | -105.32M |
| Free Cash Flow Per Share (Quarterly) | -0.5428 |
| Free Cash Flow Yield | -5.59% |